Sarclisa Market Report 2026

Sarclisa Market Overview

• The Sarclisa market growth in the historic period has been driven by increasing prevalence of multiple myeloma, advancements in monoclonal antibody development • Market expansion is supported by increasing investments in next-generation oncology drugs, growing focus on combination immunotherapies • Growth Driver: Rising Cancer Prevalence Drives Growth In The Sarclisa Market • Market Trend: Regulatory Approvals Drive Growth In The Sarclisa Market For Newly Diagnosed Multiple Myeloma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sarclisa Market?

Sarclisa is a monoclonal antibody used in the treatment of certain cancers, specifically multiple myeloma, a type of blood cancer. It works by targeting and binding to a protein called CD38, which is found on the surface of multiple myeloma cells. By binding to CD38, sarclisa helps the immune system recognize and destroy these cancerous cells. It is typically used in combination with other cancer therapies to improve treatment outcomes. The main types of sarclisa formulations are injectable solution and lyophilized powder for injection. Relapsed or refractory multiple myeloma is a stage of multiple myeloma where the disease returns after initial treatment or no longer responds to therapy. It is used for relapsed or refractory multiple myeloma and newly diagnosed multiple myeloma and is distributed through both hospital and retail pharmacies.

What Is The Sarclisa Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in next-generation oncology drugs, growing focus on combination immunotherapies, expansion of personalized cancer treatment approaches, rising demand for targeted biologics, increasing regulatory approvals for novel myeloma therapies. Major trends in the forecast period include increasing adoption of cd38-targeted monoclonal antibody therapies, rising use of combination treatment regimens, growing focus on personalized oncology care, expansion of advanced biologics manufacturing capabilities, enhanced emphasis on treatment efficacy and safety.

Global Sarclisa Market Segmentation

1) By Formulation: Injectable Solution, Lyophilized Powder for Injection 2) By Clinical Indication: Relapsed Or Refractory Multiple Myeloma, Newly Diagnosed Multiple Myeloma 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

What Are The Drivers Of The Sarclisa Market?

The increasing prevalence of cancer is expected to propel the growth of the sarclisa market going forward. Cancer is a group of diseases characterized by uncontrolled cell growth and division, which can invade surrounding tissues and spread to other parts of the body, often forming tumors or metastases, and can affect various organs or systems. The increasing prevalence of cancer can be attributed to factors such as an aging population, lifestyle choices, environmental exposures, genetic predispositions, and improved detection methods leading to better diagnosis. Sarclisa is essential for treating cancer, particularly multiple myeloma, as it targets and eliminates cancerous plasma cells, bolstering the immune system's capacity to combat the disease and enhancing treatment effectiveness. For instance, in November 2024, according to PubMed, a US-based biomedical and life sciences literature database, reported that by 2050, 35.3 million cancer cases worldwide are expected, a 76.6% increase from the 2022 estimate of 20 million. Similarly, 18.5 million cancer deaths are projected by 2050, an 89.7% increase from the 2022 estimate of 9.7 million. Therefore, the increasing prevalence of cancer is driving the growth of the sarclisa industry. The growing geriatric population is expected to propel the growth of the sarclisa market going forward. The geriatric population refers to older adults, typically those aged 65 and above, who often experience distinct health, social, and economic challenges as they age. The geriatric population is rising due to factors such as longer life expectancy, advances in healthcare, and declining birth rates, which collectively contribute to an aging global population. Sarclisa is crucial for the geriatric population as it provides an effective treatment option for multiple myeloma, especially for older adults who may not qualify for intensive therapies such as autologous stem cell transplants. For instance, in October 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, it is anticipated that one in six people worldwide would be 60 years of age or older by 2030. By 2050, this group is predicted to have doubled in size from its current size to 2.1 billion. Therefore, the growing geriatric population will drive the growth of the sarclisa industry.

Key Players In The Global Sarclisa Market

Major companies operating in the sarclisa market are Sanofi S.A.

Global Sarclisa Market Trends and Insights

Major companies operating in the Sarclisa market are focusing on developing anti CD38 monoclonal antibody therapies to meet the rising demand for effective first-line treatments in newly diagnosed multiple myeloma patients. Sarclisa (isatuximab) binds to the CD38 receptor on multiple myeloma cells, triggering tumor cell death and immune modulation. Unlike traditional therapies, it offers targeted action and deeper responses when combined with standard-of-care drugs. For instance, in September 2024, Sanofi SA, a France-based pharmaceutical company, launched Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant. This approval was based on the IMROZ phase 3 study, showing a 40% reduction in disease progression or death compared to VRd alone.

Regional Insights

North America was the largest region in the sarclisa market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sarclisa Market?

The sarclisa market consists of sales of chemotherapy agents, immunotherapy drugs, biosimilars, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sarclisa Market Report 2026?

The sarclisa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sarclisa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.